High ROIC Stocks
LNTH is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
LANTHEUS HOLDINGS INC (LNTH) Stock Price & Overview
NASDAQ:LNTH • US5165441032
Current stock price
81.205 USD
+0.61 (+0.76%)
Last:
The current stock price of LNTH is 81.205 USD. Today LNTH is up by 0.76%. In the past month the price increased by 0.21%. In the past year, price decreased by -20.99%.
LNTH Key Statistics
52-Week Range47.25 - 108.91
Current LNTH stock price positioned within its 52-week range.
1-Month Range72.375 - 82.44
Current LNTH stock price positioned within its 1-month range.
- Market Cap
- 5.276B
- P/E
- 13.44
- Fwd P/E
- 15.33
- EPS (TTM)
- 6.04
- Dividend Yield
- N/A
LNTH Stock Performance
Today
+0.76%
1 Week
+5.90%
1 Month
+0.21%
3 Months
+19.29%
Longer-term
6 Months +50.52%
1 Year -20.99%
2 Years +21.12%
3 Years -5.69%
5 Years +240.04%
10 Years +3,812.14%
LNTH Stock Chart
LNTH Stock Screens
LNTH currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
LNTH is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
High Quality Stocks
LNTH is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
LNTH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LNTH. When comparing the yearly performance of all stocks, LNTH is a bad performer in the overall market: 70.16% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
LNTH Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to LNTH. Both the health and profitability get an excellent rating, making LNTH a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LNTH Earnings
On February 26, 2026 LNTH reported an EPS of 1.67 and a revenue of 406.79M. The company beat EPS expectations (40.21% surprise) and beat revenue expectations (8.42% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$1.67
Revenue Reported406.786M
EPS Surprise 40.21%
Revenue Surprise 8.42%
LNTH Forecast & Estimates
19 analysts have analysed LNTH and the average price target is 90.39 USD. This implies a price increase of 11.31% is expected in the next year compared to the current price of 81.205.
For the next year, analysts expect an EPS growth of -12.3% and a revenue growth -3.33% for LNTH
Analysts
Analysts82.11
Price Target90.39 (11.31%)
EPS Next Y-12.3%
Revenue Next Year-3.33%
LNTH Groups
Sector & Classification
LNTH Financial Highlights
Over the last trailing twelve months LNTH reported a non-GAAP Earnings per Share(EPS) of 6.04. The EPS decreased by -10.91% compared to the year before.
Income Statements
Revenue(TTM)1.54B
Net Income(TTM)233.56M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.15% | ||
| ROA | 10.49% | ||
| ROE | 21.43% | ||
| Debt/Equity | 0.52 |
Chartmill High Growth Momentum
EPS Q2Q%5.03%
Sales Q2Q%4.01%
EPS 1Y (TTM)-10.91%
Revenue 1Y (TTM)0.5%
LNTH Ownership
Ownership
Inst Owners109.13%
Shares64.97M
Float63.59M
Ins Owners0.68%
Short Float %8.77%
Short Ratio5.6
LNTH Competitors/Peers
The largest stocks on the US markets in the "Health Care Supplies" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 31.27 | 59.904B | ||
| COO | COOPER COS INC/THE | 14.08 | 13.894B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.6 | 12.341B | ||
| SOLV | SOLVENTUM CORP | 10.17 | 11.409B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 17.07 | 4.072B | ||
| ICUI | ICU MEDICAL INC | 15.44 | 3.141B | ||
| HAE | HAEMONETICS CORP/MASS | 11.18 | 2.664B | ||
| XRAY | DENTSPLY SIRONA INC | 8.19 | 2.339B | ||
| NEOG | NEOGEN CORP | 27.7 | 2.049B | ||
| UFPT | UFP TECHNOLOGIES INC | 20.02 | 1.552B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.309B | ||
| BVS | BIOVENTUS INC - A | 12.42 | 753.339M |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LNTH
Company Profile
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 1,193 full-time employees. The company went IPO on 2015-06-25. The firm's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The firm's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The firm's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The firm's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
Company Info
IPO: 2015-06-25
LANTHEUS HOLDINGS INC
331 Treble Cove Road
North Billerica MASSACHUSETTS 01862 US
CEO: Mary Anne Heino
Employees: 1193
Phone: 18009279800
LANTHEUS HOLDINGS INC / LNTH FAQ
What does LNTH do?
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 1,193 full-time employees. The company went IPO on 2015-06-25. The firm's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The firm's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The firm's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The firm's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
What is the stock price of LANTHEUS HOLDINGS INC today?
The current stock price of LNTH is 81.205 USD. The price increased by 0.76% in the last trading session.
What is the dividend status of LANTHEUS HOLDINGS INC?
LNTH does not pay a dividend.
What is the ChartMill rating of LANTHEUS HOLDINGS INC stock?
LNTH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for LNTH stock?
19 analysts have analysed LNTH and the average price target is 90.39 USD. This implies a price increase of 11.31% is expected in the next year compared to the current price of 81.205.
What sector and industry does LANTHEUS HOLDINGS INC belong to?
LANTHEUS HOLDINGS INC (LNTH) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How is the valuation of LANTHEUS HOLDINGS INC (LNTH) based on its PE ratio?
The PE ratio for LANTHEUS HOLDINGS INC (LNTH) is 13.44. This is based on the reported non-GAAP earnings per share of 6.04 and the current share price of 81.205 USD.